Physician profile
Windrik A Lynch
NPI 1720345754
$17,576.34
in general payments reported to CMS, 2019-2025
28 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what 96% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $2,435 · 2021: $2,248 · 2022: $8,622 · 2023: $606 · 2024: $1,326 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,625 · Travel and Lodging: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.91 |
| Travel and Lodging | $911.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $11,345.01 | 2019-2024 | Senza, Vyrsa V1 |
| Medtronic USA, INC. | $999.01 | 2019-2020 | |
| Medtronic, INC. | $791.64 | 2021-2024 | Intellis Adaptivestim |
| Stryker Corporation | $644.79 | 2025 | Mild Device Kit |
| Abbott Laboratories | $624.11 | 2019-2025 | Octrode, Proclaim, Eterna |
| Relievant Medsystems, INC. | $609.82 | 2022-2023 | Intracept |
| Globus Medical, INC. | $508.09 | 2025 | Senza |
| Boston Scientific Corporation | $482.90 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept |
| Collegium Pharmaceutical, INC. | $338.63 | 2019-2025 | Xtampza, Belbuca |
| Cerapedics INC. | $331.50 | 2023-2025 | I-Factor Peptide Enhanced Bone Graft |
| Nuvasive, INC. | $231.97 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $136.71 | 2022-2024 | Ztlido |
| Painteq LLC | $103.77 | 2022 | |
| 4web, INC. | $66.46 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.19 | 2024-2025 | Relistor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $46.25 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $32.30 | 2024-2025 | |
| Depuy Synthes Sales INC. | $31.32 | 2019 | |
| Pfizer INC. | $28.89 | 2019-2021 | |
| Almatica Pharma LLC | $28.03 | 2022 | |
| Smith+Nephew, INC. | $23.18 | 2025 | Fast-Fix |
| Spr Therapeutics, INC | $18.47 | 2025 | Sprint Pns System |
| Pacira Pharmaceuticals Incorporated | $17.96 | 2025 | Iovera, Zilretta |
| Heron Therapeutics, INC. | $17.81 | 2025 | Aponvie |
| Ibsa Pharma INC. | $17.69 | 2025 | Tirosint, Licart, Flector |
| Averitas Pharma INC. | $17.08 | 2025 | Qutenza |
| Kowa Pharmaceuticals America, INC. | $15.48 | 2022 | |
| Assertio Therapeutics, INC. | $14.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Windrik Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.